<DOC>
	<DOCNO>NCT01877642</DOCNO>
	<brief_summary>This study compare safety effect time give ADASUVE lorazepam ( intramuscular ) compare agent give alone .</brief_summary>
	<brief_title>ADASUVE-Lorazepam Drug-Drug Interaction</brief_title>
	<detailed_description>The objective study compare safety pharmacodynamic profile concomitant administration single dose ADASUVE lorazepam ( IM ) compare agent administer alone . Respiratory pharmacodynamics monitor recording respirations/minute pulse oximetry . Other pharmacodynamic safety measure include effect blood pressure , heart rate , sedation psychomotor measure attention , information processing speed , reaction time , coordination . Initially , 4 subject receive lorazepam 1 mg IM + ADASUVE 10 mg open label validate dose regimen . After safety data review dose regimen confirm , 18 non-obese , healthy male female volunteer age 18 50 enrol double-blinded , double-dummy , randomize , 3-period cross-over drug interaction study .</detailed_description>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Loxapine</mesh_term>
	<criteria>Male female subject age 18 50 year , inclusive . Body mass index ( BMI ) ≥18 ≤32 . Subjects willing able comply study schedule requirement , stay CRU 9 day . Subjects speak , read , understand English willing able provide write informed consent IRB approve form prior initiation study procedure . Subjects good general health prior study participation determine detailed medical history , physical examination , 12lead ECG , blood chemistry profile , hematology , urinalysis , opinion Principal Investigator . Female participant ( childbearing potential sexually active ) agree use medically acceptable effective birth control method throughout study 30 day follow end study Male participant ( sexually active partner childbearing potential ) agree use medically acceptable effective birth control method first dose 90 day follow last dose study drug . Male participant must refrain donating sperm period . Subject history , include : cardiovascular disease disorder ; asthma , chronic obstructive lung disease , use inhaler prescribed wheeze bronchospasm must exclude ; sleep apnea ; acute narrowangle glaucoma ; neurological , gastrointestinal , hepatic , renal , hematologic , endocrine and/or metabolic disease disorder ; psychiatric illness mental disorder except short term situational anxiety depression &lt; 2 year duration ; substance abuse addiction within last 2 year ; pregnancy within past 6 month . Subjects take prescription nonprescription medication within 7 day Visit 2 . Subjects acute illness within last 7 day Visit 2 . Subjects history HIV positivity . Subjects test positive alcohol positive urine drug screen . Subjects history allergy intolerance loxapine amoxapine . Subjects history allergy intolerance lorazepam benzodiazepine . Subjects history allergy intolerance polyethylene glycol , propylene glycol , benzyl alcohol Female subject positive pregnancy test screen admission Visit 2 , breastfeed . Subjects receive investigational drug within 30 day prior Screening Visit . Subjects disease ( ) , history , physical examination , laboratory abnormality , investigator 's opinion , present undue risk subject may confound interpretation study result . Subjects consider investigator , reason , unsuitable candidate receive lorazepam ADASUVE .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ADASUVE</keyword>
	<keyword>inhaled loxapine</keyword>
	<keyword>drug drug interaction</keyword>
	<keyword>lorazepam</keyword>
	<keyword>acute treatment agitation</keyword>
</DOC>